Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma - GASD syndrome by TNF antagonists.

Authors

Jörg C Prinz, Pia-Charlotte Stadler

Published in

Frontiers in immunology. Volume 17. Pages 1726457. Epub Jun 09, 2026.

Abstract

Patients treated with TNF-α antagonists may develop psoriasis-like skin lesions. Clinical manifestations include palmoplantar, inverse, localized or generalized guttate, plaque-type, eczematous, and pustular lesions; deep inflammatory nodes; and nonscarring alopecia, often with overlapping reaction patterns. They are classified as paradoxical psoriasis and interpreted as an inflammatory reaction resulting from the disturbed maturation of plasmacytoid dendritic cells, with overproduction of type I interferons due to tumor necrosis factor α (TNF-α) inhibition. Management frequently necessitates discontinuation of therapy. Here, we review the clinical presentation of six patients who were initially diagnosed with paradoxical psoriasis during TNF-α blockade due to the development of corresponding skin lesions. Dermatologic examination revealed that the lesions were impetigo contagiosa, ecthyma, folliculitis decalvans, ostiofolliculitis, nummular microbial eczema, or abscessing furunculosis-all caused by Staphylococcus aureus, likely spreading from the colonized nasal mucosa to the skin. The cutaneous symptoms resolved with topical antimicrobial therapy and systemic antibiotic treatment. We conclude that many cases diagnosed as paradoxical psoriasis may, in fact, represent generalized abscessing staphyloderma resulting from impaired antimicrobial immunity under TNF-α blockade. The diagnosis of paradoxical psoriasis should therefore be critically re-evaluated on a case-by-case basis. Identification and eradication of S. aureus may substantially improve the prognosis for patients experiencing paradoxical psoriasis-like manifestations during treatment with TNF-α antagonists.

PMID:
42344923
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.